title: Bone edema determined by magnetic resonance imaging reflects severe disease status in patients with early-stage rheumatoid arthritis.
abstract: OBJECTIVE
  To determine the significance of bone edema, detected by magnetic resonance imaging (MRI), in early-stage rheumatoid arthritis (RA).
  
  
  METHODS
  We simultaneously examined serologic variables, MRI of wrist sites and finger joints of both hands, clinical disease activity score (DAS), and HLA-DR typing at entry in 80 patients with early-stage RA.
  
  
  RESULTS
  The number of bones scored as positive for bone edema correlated with the number of sites scored as positive for MRI synovitis and MRI bone erosion, rate of enhancement (E-rate), and serum C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and interleukin 6 (IL-6). Findings for MRI synovitis and MRI bone erosion, E-rate, CRP, MMP-3, IL-6, seropositivity, and titer of anti-cyclic citrullinated peptide antibody (anti-CCP antibody), DAS28-CRP and HLA-DRB1*0405 allele carriership, were significantly higher in the positive versus the negative bone edema group.
  
  
  CONCLUSIONS
  Bone edema based on our scoring system may reflect severe disease status in patients with early-stage RA. However, its clinical value at entry in prognostication of RA should be examined through prospective clinical followup studies.
authors.affiliation: First Department of Internal Medicine, Graduate School of Biomedical Sciences, School of Health Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki, Japan.
authors.forename: Mami
authors.initials: M
authors.lastname: Tamai
authors.forename: Atsushi
authors.initials: A
authors.lastname: Kawakami
authors.forename: Masataka
authors.initials: M
authors.lastname: Uetani
authors.forename: Shoichiro
authors.initials: S
authors.lastname: Takao
authors.forename: Fumiko
authors.initials: F
authors.lastname: Tanaka
authors.forename: Keita
authors.initials: K
authors.lastname: Fujikawa
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Aramaki
authors.forename: Hideki
authors.initials: H
authors.lastname: Nakamura
authors.forename: Nozomi
authors.initials: N
authors.lastname: Iwanaga
authors.forename: Yasumori
authors.initials: Y
authors.lastname: Izumi
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Arima
authors.forename: Kouichiro
authors.initials: K
authors.lastname: Aratake
authors.forename: Makoto
authors.initials: M
authors.lastname: Kamachi
authors.forename: Mingguo
authors.initials: M
authors.lastname: Huang
authors.forename: Tomoki
authors.initials: T
authors.lastname: Origuchi
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Ida
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Aoyagi
authors.forename: Katsumi
authors.initials: K
authors.lastname: Eguchi
mesh_terms: D001172:Arthritis, Rheumatoid / Q000097:blood / Q000235:genetics / Q000276:immunology / Q000473:pathology*; D001323:Autoantibodies / Q000097:blood; D001842:Bone and Bones / Q000473:pathology*; D002097:C-Reactive Protein / Q000378:metabolism; D004487:Edema / Q000473:pathology*; D006684:HLA-DR Antigens / Q000235:genetics; D059811:HLA-DRB1 Chains; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D008279:Magnetic Resonance Imaging; D019278:Matrix Metalloproteinase 3 / Q000097:blood; D010456:Peptides, Cyclic / Q000276:immunology; D011379:Prognosis; D013585:Synovitis / Q000473:pathology
chemical_list: D001323:Autoantibodies; D006684:HLA-DR Antigens; D059811:HLA-DRB1 Chains; C493960:HLA-DRB1*04:05 antigen; C508600:IL6 protein, human; D015850:Interleukin-6; D010456:Peptides, Cyclic; C487763:cyclic citrullinated peptide; D002097:C-Reactive Protein; C511768:MMP3 protein, human; D019278:Matrix Metalloproteinase 3